<DOC>
	<DOCNO>NCT00003426</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness gemcitabine plus radiation therapy treat patient pancreatic cancer surgically remove .</brief_summary>
	<brief_title>Gemcitabine Plus Radiation Therapy Treating Patients With Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose gemcitabine combination radiation therapy patient locally advance and/or unresectable adenocarcinoma pancreas . II . Determine dose limit toxic effect combination therapy patient . III . Evaluate ability patient tolerate induction maintenance therapy gemcitabine precede follow combination therapy . IV . Evaluate efficacy ( response rate , pattern failure , survival ) combination therapy patient . OUTLINE : This dose escalation study gemcitabine . Part I : Patients receive gemcitabine continuous infusion 30 minute weekly 3 week follow 1 week rest . Part II : Gemcitabine IV administer 30 minute infusion twice week ( Monday Thursday ) 5-6 week . Patients receive radiation therapy 5 day week 5-6 week . In absence dose-limiting toxicity ( DLT ) first 6 patient treat , subsequent cohort 6 patient receive escalate dos gemcitabine schedule . If DLT occur 2 6 patient give dose level , dose escalation cease next low dose declare maximum tolerated dose . Part III : In absence toxicity disease progression , patient continue gemcitabine 3 additional course . Maintenance gemcitabine start 4 week completion radiation therapy administer weekly 3 week follow 1 week rest . Patients follow death . PROJECTED ACCRUAL : This study accrue 15-30 patient approximately 24 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven locally advanced and/or unresectable adenocarcinoma pancreas No metastatic disease No completely resect pancreatic cancer PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % OR ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No congestive heart failure No New York Heart Association class III IV heart disease Other : Not pregnant No concurrent medical problem would increase side effect morbidity chemoradiation No concurrent medical condition would make patient ineligible receive external beam radiation : Crohn 's disease Inflammatory bowel disease No active infection require systemic antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior gemcitabine No prior chemotherapy pancreatic cancer Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy pancreas Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>